Vanda Pharma Q4 2023 GAAP EPS $(0.04) Beats $(0.09) Estimate, Sales $45.27M Beat $37.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharma (NASDAQ:VNDA) reported Q4 2023 earnings with a GAAP EPS of $(0.04), surpassing the $(0.09) estimate. Sales reached $45.27M, exceeding the $37.00M forecast but marking a 29.79% decrease from the previous year.
February 07, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vanda Pharma's Q4 2023 earnings exceeded analyst expectations with a smaller loss per share and higher sales than forecasted, though sales dropped compared to last year.
Beating both EPS and sales estimates typically has a positive impact on a company's stock price in the short term. However, the significant year-on-year sales decrease might temper investor enthusiasm, suggesting a cautious optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100